Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Portage Biotech Inc

Healthcare US PRTG

NoneUSD
0.00(0%)

Last update at 2025-11-20T20:10:37.287907Z

Day Range

--
LowHigh

52 Week Range

0.204.40
LowHigh

Fundamentals

  • Previous Close 4.70
  • Market Cap5.20M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-18.92800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-8.52

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -122.52200M -14.81700M -14.89200M -5.08400M -3.59400M
Minority interest 0.06M 2.30M 46.15M 49.11M 48.88M
Net income -104.61100M -19.16900M -17.18900M -7.24900M -2.63500M
Selling general administrative 8.36M 8.82M 5.13M 1.87M 1.87M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.00100M - - - -
Ebit -16.61900M -15.58800M -12.44000M -5.97800M -3.03200M
Ebitda -16.61800M -15.65000M -14.18600M -5.94900M -2.81500M
Depreciation and amortization 0.00100M -0.06200M -1.74600M 0.03M 0.22M
Non operating income net other - - - - -
Operating income -16.57500M -15.58800M -12.44000M -5.97800M -2.76400M
Other operating expenses 16.58M 15.59M 12.44M 5.98M 2.76M
Interest expense 0.00900M 0.04M 0.18M 0.56M 0.09M
Tax provision -17.85600M 4.35M 2.30M 2.17M -
Interest income 0.22M 0.00000M 0.00000M 0.01M 0.11M
Net interest income 0.21M -0.04300M -0.17700M -0.54600M 0.02M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -17.85600M 4.35M 2.30M 2.17M -0.21700M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 16.58M 15.59M 12.44M 5.98M 2.76M
Cost of revenue - - - - -
Total other income expense net -106.15400M 0.77M -2.45200M 0.89M -0.85300M
Discontinued operations - - - - -
Net income from continuing ops -104.66600M -19.16900M -17.18900M -7.24900M -3.59400M
Net income applicable to common shares - -16.87000M -15.83300M -5.33300M -2.63500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 99.13M 194.66M 174.86M 173.17M 173.72M
Intangible assets 81.68M 117.39M 117.39M 117.39M 117.39M
Earning assets - - - - -
Other current assets 0.12M 1.27M 1.49M 0.23M 0.23M
Total liab 23.73M 29.23M 27.26M 27.53M 25.16M
Total stockholder equity 76.05M 121.20M 101.45M 96.53M 99.67M
Deferred long term liab - 117.39M 117.39M 117.39M 117.39M
Other current liab 1.59M 0.59M 1.12M 1.93M 0.02M
Common stock 218.78M 158.32M 130.65M 117.82M 116.24M
Capital stock 218.78M 158.32M 130.65M 117.82M 116.24M
Retained earnings -159.61600M -55.00500M -38.13500M -22.30200M -16.96900M
Other liab - 28.45M 24.05M 21.60M 20.36M
Good will 0.00000M 43.32M 43.32M 43.32M 43.32M
Other assets - 117.42M 117.45M 117.42M 117.43M
Cash 10.54M 23.35M 2.77M 3.15M 6.17M
Cash and equivalents - - - - -
Total current liabilities 1.86M 0.78M 3.21M 2.57M 1.79M
Current deferred revenue - - - 0.72M 0.72M
Net debt -10.54500M -23.35200M -2.62000M 0.51M -2.50300M
Short term debt - - 0.15M 0.30M 0.66M
Short long term debt - - 0.15M 0.30M 0.66M
Short long term debt total - - 0.15M 3.66M 3.66M
Other stockholder equity 21.20M 16.93M 7.98M 0.06M 0.32M
Property plant equipment - - - - -
Total current assets 13.68M 24.83M 4.95M 3.79M 6.55M
Long term investments 2.89M 9.08M 9.14M 8.63M 6.41M
Net tangible assets - 77.88M 58.12M 53.21M 56.35M
Short term investments - - 0.00000M 0.07M 0.10M
Net receivables 0.68M 0.21M 2.18M 0.06M 0.06M
Long term debt - - - 3.36M 3.00M
Inventory - - - - -
Accounts payable 0.27M 0.19M 1.94M 0.34M 0.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -4.32500M 0.96M 0.96M 0.96M 0.08M
Additional paid in capital - - - - -
Common stock total equity - - 130.65M 117.82M 116.24M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.88M 0.04M 0.06M 0.03M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 85.45M 169.83M 169.91M 169.38M 167.16M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -0.61700M 0.00000M -0.86000M -0.86000M -0.68800M
Change to liabilities 1.11M -1.21200M 0.88M 0.17M 0.36M
Total cashflows from investing activities -0.61700M -0.61700M -0.86000M -0.86000M -0.44600M
Net borrowings -2.00000M -2.00000M -1.97000M 0.70M -0.05000M
Total cash from financing activities -0.11700M 27.35M 4.76M 0.70M -0.05000M
Change to operating activities -1.09300M 0.23M -1.51300M -0.28100M 0.35M
Net income -104.66600M -19.16900M -17.18900M -7.24900M -3.59400M
Change in cash -12.80700M 20.58M -0.38200M -3.01400M -1.35400M
Begin period cash flow 23.35M 2.77M 3.15M 6.17M 7.52M
End period cash flow 10.54M 23.35M 2.77M 3.15M 6.17M
Total cash from operating activities -12.07300M -6.76400M -4.28400M -3.71400M -0.85800M
Issuance of capital stock 2.98M 29.09M 6.98M - -
Depreciation 0.00100M 0.00100M 1.02M 0.27M -
Other cashflows from investing activities -0.61400M -0.61400M -0.61400M -0.61400M -0.95000M
Dividends paid - - - - -
Change to inventory - 1.21M -0.88000M - -
Change to account receivables -0.03100M 0.52M -0.11100M -0.11100M -0.11100M
Sale purchase of stock - - - - -
Other cashflows from financing activities -1.09900M -1.74700M -1.19800M 1.00M -0.44600M
Change to netincome 92.55M 10.57M 12.22M 1.47M 1.06M
Capital expenditures 0.00300M 0.00300M 0.00300M 0.00300M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.01000M -0.46100M -0.74400M -0.11400M 0.71M
Stock based compensation 4.28M 9.14M 8.83M 2.16M 1.17M
Other non cash items 106.21M -0.67000M 1.36M 1.49M 0.85M
Free cash flow -12.07600M -6.76400M -4.28400M -3.71400M -0.85800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PRTG
Portage Biotech Inc		 - -% - - - - 0.28 -0.0231
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Portage Biotech Inc

Clarence Thomas Building, Tortola, British Virgin Islands, VG1110

Key Executives

Name Title Year Born
Dr. Ian B. Walters M.B.A., M.D. CEO & Chairman of Board 1968
Mr. Allan J. Lee Shaw CPA Chief Financial Officer 1964
Mr. Steven Innaimo VP of Project Management & Operations NA
Dr. Robert A. Kramer Ph.D. Chief Scientific Officer NA
Mr. Brian Wiley Chief Bus. Officer 1968
Mr. Joseph Ciavarella Chief Accounting Officer NA
Mr. Brian Wiley Chief Business Officer 1968
Mr. Justin Fairchild Vice President of Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions